PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

The changing landscape of AML

Using bioinformatics and genomics to treat AML

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

Novel methods of drug testing and biopsy in India

Cutting-edge cancer care at the Miami Cancer Institute

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL